Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission 
DOJ Subpoenas New York Times Journalists Over Air Force One Leak Report 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Singapore GDP Grows 5.7% in Q2 2026 as AI-Driven Manufacturing Boosts Economy 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
DOJ Orders Crackdown on Birth Tourism After Supreme Court Upholds Birthright Citizenship 
South Korea Central Bank Set to Raise Interest Rates as Inflation Stays Elevated 
In a rebuke to Trump, the Supreme Court rules that birthright citizenship is the law of the land 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
